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Triglyceride synthesisDiacylglycerol acyltransferase 1 (DGAT1) is a microsomal membrane enzyme responsible for the ﬁnal step in the
synthesis of triacylglycerides. Although DGATs from a wide range of organisms have nearly identical sequences,
there is little structural information available for these enzymes. The substrate binding sites of DGAT1 are
predicted to be in its large luminal extramembranous loop and to include common motifs with acyl-CoA
cholesterol acyltransferase enzymes and the diacylglycerol binding domain found in protein kinases.
In this study, synthetic peptides corresponding to the predicted binding sites of DGAT1 enzyme were examined
using synchrotron radiation circular dichroism spectroscopy, ﬂuorescence emission and adsorption onto lipid
monolayers to determine their interactions with substrates associated with triacylglyceride synthesis (oleoyl-
CoA and dioleoylglycerol). One of the peptides, Sit1, which includes the FYxDWWN motif common to both
DGAT1 and acyl-CoA cholesterol acyltransferase, changes its conformation in the presence of both substrates,
suggesting its capability to bind their acyl chains. The other peptide (Sit2), which includes the putative
diacylglycerol binding domain HKWCIRHFYKP found in protein kinase C and diacylglycerol kinases, appears to
interact with the charged headgroup region of the substrates. Moreover, in an extended-peptide which contains
Sit1 and Sit2 sequences separated by a ﬂexible linker, larger conformational changes were induced by both
substrates, suggesting that the two binding sites may bring the substrates into close proximity within the
membrane, thus catalyzing the formation of the triacylglyceride product.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The acyl-CoA:diacylglycerolacyltransferase 1 (DGAT1) is a micro-
somal enzyme located mainly in the endoplasmic reticulum (ER)
membrane; it plays an essential role in lipid metabolism by catalyzing
the production of triglycerides from acyl-CoA and diacylglycerol
substrates [1,2]. Disfunction in this stage of lipid metabolism can lead
to serious disorders, such as obesity, which is an important risk factor
for cardiovascular diseases, hypertension and diabetes [3,4]. Transgenic
DGAT1-deﬁcient mice have been shown to resist induced obesity even
when fed on a rich fat-based diet, in addition to showing a remarkable
reduction in the accumulation of triacylglycerol in their adipose tissues
[5]. This suggests that DGAT1 enzymes could be potential therapeuticao Carlos 13563-120, Brazil.
WC1E 7HX, UK. Tel.: +44 207
, b.wallace@mail.cryst.bbk.ac.uktargets for the inhibition of obesity [6–9]. In addition, DGAT1 is an
important element in food production/agriculture as cattle milk-fat
production can be greatly enhanced by a single point mutation in this
enzyme [10].
Although DGAT orthologues from a wide variety of mammalian
sources have nearly identical sequences (~90%), and even orthologues
from distantly related eukaryotes have identities of N40%, there is as
yet no crystal structure of any DGAT protein nor of any closely-related
protein whichmight form a good template for modeling of its structure.
Bioinformatics analyses indicate that it is an integral membrane protein
[11], but that its enzymatic function lies in a large luminal loop in the C-
terminal half of the protein. Two peptides in this loop are thought to
comprise the binding sites for the two types of substrates: Sit1, which
includes the motif FYxDWWN [12] that is highly conserved between
the DGAT and acyl-CoA cholesterol acyltransferase (ACAT) enzymes
[13,14] (356FGDREFYRDWWNSES370), and Sit2, which includes the
putative diacylglycerol binding motif HKWCIRHFYKP found in protein
kinase C and diacylglycerol kinases (
379
NIPVHKWSIRHFY391). In this
study, we have examined substrate interactions involving synthetic
peptides corresponding to these two motifs, as well as with a third
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by a short ﬂexible linker. The Sit1 and Sit2 sequences are located in the
same extramembranous loop as the proposed catalytic residue, His416,
albeit at some distance from it in the linear sequence. It has been
suggested that the two proposed binding sites may be important for
directing the substrates into an extended active site, making them
available for reaction at the catalytic histidine. Hence, the interactions
of the peptides with the oleoyl-CoA and dioleoylglycerol substrates
were examined using synchrotron radiation circular dichroism (SRCD)
and ﬂuorescence spectroscopies, and adsorption onto lipid monolayers.2. Materials and methods
2.1. Materials
1,2-Dioleoyl-sn-glycerol (DOG) and coenzyme A (CoA) were
purchased fromSigmaAldrich; oleoyl coenzymeA (OCoA) and the phos-
pholipid 1-palmitoyl-2-oleoyl-sn-glycerol-3-phospho-rac-(1-glycerol)
(POPG) were purchased from Avanti Polar Lipids.
The synthetic peptides were designed based on the primary struc-
ture of bovine DGAT1 (UniProt code Q8MK44). Sit1 (its location within
the full length protein is noted in Fig. 1) includes the most conserved
region present in DGAT1 and the ACAT family, the FYxDWWN segment.
Sit2 is the putative diacylglycerol binding domain, and includes the
sequence HKWCIRHFYKP, similar to that found in protein kinase C and
the diacylglycerol kinases. A third peptide, Sit1&2, links together the
most conserved residues of Sit1 and Sit2 with a ﬂexible linker region
with the sequence GSG (peptide sequences are in Suppl. Table 1).
Peptides were manually synthesized using Fmoc strategy on Rink
AmideMBHA resin. Coupling reactions were performedwith two equiv-
alents of Fmoc-protected amino acids, N,N′-diisopropylcarbodimide/
N-hydroxybenzotriazole in dimethylformamide (DMF) (1:1, volume
ratio) until reaction went to N95% completion, as checked by Kaiser
assay [15], and deblockings were done with 20% piperidine in
DMF. After the incorporation of all amino acid residues, the ﬁnal
cleavage of the peptide from the resin was performed with a mixture
of triﬂuoroacetic acid (TFA):triisopropylsilane:ethanedithiol:H2O
(94:1:2.5:2.5, v/v) for 4 h. The crude peptides were precipitated with
cold diethyl ether, centrifuged and lyophilized. The synthetic peptides
were solubilized in 0.1% (v/v) TFA and the puriﬁcation was carried
out with semi-preparative HPLC using a reverse-phase C18 column
(Vydac, Hesperia, CA) equilibrated with 0.1% (v/v) TFA/water. The
peptides were eluted from the column with a linear gradient from 5%
to 95% of acetonitrile in water containing 0.1% TFA using a 2 mL/min
ﬂow rate, over a 30 min gradient and with absorbance monitored at
220 and 280 nm (Suppl. Fig. 1a). The sequences of the puriﬁed peptides
were conﬁrmed by mass spectrometry analyses using an ESI-
microOTOF-Q (Bruker Daltonics). Peptides were solubilized in formic
acid 0.5% and analyzed in the 50–3000 m/z range (Suppl. Fig. 2).
Peptide concentrations were determined by measuring the absor-
bance at 280 nm, using their calculated molar extinction coefﬁcients
[16].2.2. Prediction of secondary structure propensity and transmembrane
segments
The secondary structure propensities of the peptides were calculat-
ed based on the sequences as found in the full length bovine DGAT1
enzyme and in the isolated peptides using the GOR [17] method. The
prediction of transmembrane segments in DGAT1 used the SACS
MEMSAT software [11] to produce Fig. 1A.Fig. 1. Transmembrane (TM) and secondary structure predictions forDGAT1 enzyme. A) Predict
region is indicated in orange. In both cases the locations of the Sit1 and Sit2 peptides are in green
structure code is c, coil; e extended; and h, helix.2.3. Monolayer surface activity
The surface activities of the Sit1, Sit2 and Sit1&2 peptides were
measured in a Kibron trough (Kibron, Finland) by injection of the pep-
tides (10 μM) into the aqueous subphase and recording the surface
pressure over 30 min. To measure the kinetics of the adsorption
of these peptides onto monolayers formed by 1-palmitoyl-2-oleoyl-
sn-glycerol-3-phosglycerol (POPG) and dioleoyl glycerol (DOG), each
lipid was solubilized in a mixture of chloroform/methanol (4:1) and
spread on the top of the water to achieve surface pressures ranging
from 5 to 40 mN/m. After solvent evaporation, each of the DGAT1
peptides (10 μM)was injected in the subphase, and the surface pressure
recorded as a function of time.2.4. Synchrotron radiation circular dichroism spectroscopy in solution
SRCD spectra of each of the peptides in an aqueous solution
(0.3 mM) and in the presence of oleoyl-CoA (OCoA) at 1:1, 1:2 and
1:4 peptide:lipid molar ratios were measured on beamline CD1 at the
Institute for Storage Ring facilities (Aarhus, Denmark). Triplicate scans
of samples and baselines (taken using the same exact condition of the
cognate sample, containing all of the components in the sample, except
the peptide) were obtained over the wavelength range from 280 to
176 nm in 1 nm increment using a 2 s dwell time in demountable
Suprasil quartz cells (Hellma Analytics, UK) with 0.0050 cm pathlength
at 25 °C. The sample and baseline scans were each averaged and the
averaged baseline subtracted from the averaged sample spectrum,
smoothed with a Savitzky–Golay ﬁlter, and calibrated with camphor-
sulfonic acid using CDTool processing software [18]. Replicate measure-
ments were also done at the DISCO beamline of the Soleil Synchrotron
(Paris, France) and at the CD12@ANKA beamline of the ANKA Synchro-
tron (Karlsruhe, Germany). Mean residue weights of 142, 141, and 141,
respectively, were used to scale the spectra of the Sit1, Sit2 and Sit1&2
peptides to delta epsilon values.
Additionally, conventional CD spectroscopy was used to investigate
the binding of the DGAT1 peptides (25 μM) to CoA at a 1:10 molar
ratio. Measurements were obtained over the wavelength from 185 to
280 nm in 1 nm intervals using a Jasco J-715 spectropolarimeter as an
average of 6 scans using a 0.1 cm pathlength quartz cuvette, at 25 °C.
Baseline subtraction and data processing were performed using CDTool
software.2.5. SRCD spectroscopy of ﬁlms
Either DOG or POPG (the latter is not a substrate but examined as a
control for speciﬁcity of the interactions) in chloroform/methanol (4:1)
was incubated with each of the DGAT1 peptides at peptide:lipid molar
ratios of 1:50. A ﬁlm of the mixture was prepared by depositing 10 μl
of the peptide/lipid mixture onto a circular Suprasil quartz plate
(Hellma Analytics, UK), then allowing the evaporation of the solvent;
the ﬁlm was further dried in a desiccator under vacuum for 3 h, and
then re-hydrated for 24 h in a specially designed sample chamber [19]
at 97% relative humidity. SRCD measurements were obtained at 25 °C,
over the wavelength range from 280 to 170 nm with 1 nm step size
and 2 s dwell time.Measurementsweremade at four different rotation-
al positions of the plate separated by 90° in the direction perpendicular
to the beam in order to detect any signal due to linear dichroism. These
four rotational repeats were averaged to produce the ﬁnal spectrum.
Baseline measurements (obtained with an empty cell) were subtracted
from the sample spectra using CDTool software.edmembrane disposition of bovine DGAT1 and B) secondary structure predictions. The TM
and cyan overlay, respectively, and the putative catalytic histidine is in red. The secondary
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Fig. 2.Behavior onmonolayers. Initial pressure (πinitial) versus the surface pressure change
(πΔ) for the adsorption of Sit1 (black square), Sit2 (white circle) and Sit1&2 (gray triangle)
on A) DOG and B) POPG monolayers formed on the surface of water with initial surface
pressures ranging from5 to 40 mN/m. Linearﬁtswere produced usingOrigin 8.5 software.
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The ﬂuorescence emission spectra of the DGAT1 peptides (25 μM) in
an aqueous solution, alone and in the presence of OCoA at 1:1, 1:2 and
1:4 molar ratios were measured on an ISS K2 spectroﬂuorimeter
(ISS Fluorescence, Analytical and Biomedical Instruments, Illinois,
USA) using a 1 cm path length quartz cuvette, at 25 °C. Samples were
excited at 295 nm and the emission spectra were recorded from 305
to 450 nm. Reference spectra of the solution were recorded and
subtracted for each sample.
The ﬂuorescence emission spectra of the DGAT peptides (25 μM)
were also measured in the presence of CoA at 1:10 molar ratio, using
the same conditions described above.
3. Results and discussion
3.1. Bioinformatics predictions
Sequence-based prediction of the transmembrane (TM) segment
disposition of the DGAT1 protein suggests that it consists of 7 TM
segments plus a large luminal extramembranous domain. The Sit1
(residues 356–370) and Sit2 (residues 379–391) peptides fall within
the extramembranous domain, as does the proposed catalytic histidine,
H416 (Fig. 1A–B). This raises the question of the nature of the extended
binding site, and if one or both of the peptides could interact with one
or both of the substrates. Secondary structure predictions indicate
that in the intact protein, the Sit1 peptide will be ~80% extended beta-
strand structure and 20% unordered (or at least not adopting one of
the canonical types of secondary structure). Not surprisingly, similar
calculations on the isolated peptide sequences produce different
proportions of extended (~50%) and unordered structures (~50%). On
the other hand, the Sit2 sequence in either context is predicted to be
~40% extended strands and ~60% disordered (Suppl. Table 2). None of
the secondary structure predictions suggest that either peptide will be
helical.
3.2. Monolayer interactions
Surface activity experiments for the peptides at a water interface
(Suppl. Fig. 1b) indicated that both Sit1 and Sit2 peptides presented a
low surface activity, although the hybrid Sit1&2 peptide promoted a
considerable change in surface pressure (Δπ ~ 8 mN m−1). The higher
surface activity of Sit1&2 is probably due to the enhancement of the
hydrophobic character of the peptide, promoted by its increased
relative proportion of hydrophobic/non-polar and aromatic residues,
which become exposed at the air–water interface. The isolated peptides
(Sit1 and Sit2) did exhibit more surface activity on the lipid monolayers
than at the water interface.
Exclusion surface pressure (πexc) (also known as a critical surface
pressure) is a parameter that determines the ability of a molecule
solubilized in the aqueous subphase to interact with, and penetrate
into a preformed lipid monolayer at the interface. In order to evaluate
this for the Sit1, Sit2 and Sit1&2 peptides, Langmuir monolayers [20]
composed of either DOG (a substrate for the enzyme) or POPG (not a
substrate, but used as a control to examine the speciﬁcity of the inter-
actions for actual substrates) were used to determine exclusion surface
pressure values.
The Sit1 peptide promoted larger changes in surface pressure values
than Sit2 (Fig. 2A) on the DOG monolayers. Sit2 essentially did not
interact with the DOG monolayer, except for minor changes at low
initial surface pressure values. This was contrary to expectations, asFig. 3. Binding to oleoyl-CoA and CoA. SRCD spectra of the peptides A and B) Sit1, C) Sit2, andD)
G) Sit2, andH) Sit1&2 in an aqueous solution (black solid line). The peptide Sit1was titratedwit
Sit1 was incubated with 0.25 mM of CoA (dash) in B) and F). The Sit2 and Sit1&2 peptides weSit2 was designed based on homology with protein kinase C and the
diacylglycerol kinases (Suppl. Fig. 4), which have the DOG substrates
in common. However, the Sit1&2 peptide was able to penetrate into
the DOG monolayer even at dense lipid packing. Therefore, synergism
seen for the combination peptide is suggested to be the result of interac-
tions of DOG with both parts of the Sit1&2 peptide.
The incorporation of the peptides into the POPG monolayers
(Fig. 2B) showed that as the initial surface pressure increased, changes
in theπ valuewere smaller due to reduced incorporation of thepeptides
in the monolayers. The induced surface activity observed for Sit2 was
higher than for Sit1, which may be simply due to the interaction
between the negatively charged lipid and the positively charged
peptide.
The exclusion surface pressure observed for Sit1 is around
35 mN m−1, which is nearly that of lipid packing in cell membrane
(25–30 mNm−1) [21]. However, for Sit2 and Sit1&2, exclusion surface
pressure is much higher, close to 50 mNm−1, which means that those
peptides are incorporated into the POPG monolayer, interacting with
the hydrophobic tails of the lipid.Sit1&2 in an aqueous solution (black solid line). Fluorescence emission spectra of E, F) Sit1,
h 0.3mMOCoA (gray), 0.6mMOCoA (dot), and 1.2mMOCoA (dash) inA) and E); and also,
re incubated with 0.25 mM of CoA (dash) in G) and H), respectively.
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Fig. 4. SRCD spectra of ﬁlms formed from substrates and non-substrates. Sit1 (solid), Sit2
(dash), Sit1&2 (dot) peptides in the presence of lipid ﬁlms composed of A) DOG
(substrate) and B) POPG (non-substrate).
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solution
SRCD spectroscopy was used to examine if any structural changes
occur in the DGAT1 peptides in the presence of the substrates. SRCD
spectroscopy, as opposed to conventional CD spectroscopy, was
employed since it provides a better signal-to-noise ratio and access
to lower wavelength, both of which are especially important for
examining peptides under the conditions used in this study, which
include high non-chiral absorption of the substrates at low UV-
wavelengths [22,23].
The SRCD spectra of the Sit1 and Sit2 peptides both exhibited very
low per-residue magnitudes (i.e. delta epsilon values) relative to those
found in proteins; this is common for peptides in solutionwhich exhibit
conformational ﬂexibility, as their net spectra arise from the weighted
sum of the many conformations present. For Sit1, in the absence of
substrate, the spectrum is characterized by a small positive peak at
~184 nm and a larger negative peak at ~198 nm; the latter is often
characteristic of disordered structures (Fig. 3A). It has no negative
peaks in the region from 207 to 224 nm, which are typically character-
istic for ordered secondary structures, but it does have a negative peak
at ~228 nm, which could arise from exciton interactions of the adjacent
Trp aromatic residues in this peptide [24,25]. Interestingly, upon
binding OCoA, the 198 nm peak disappears and is replaced by a peak
at ~207 nm, and the 184 nm peak red-shifts and increases in magni-
tude; both of these changes suggest an increase in ordering (or decrease
in disorder), perhaps due to the formation of a small beta-strand-like
structure. The 228 nm peak does not shift, but does increase in magni-
tude; again suggestive of an increased proportion of order (or decreased
ﬂexibility) producing increased aromatic side chain interactions. These
results are consistentwith there being a signiﬁcant interaction between
this peptide and the acyl-CoA substrate. Furthermore the changes seen
tend to mimic the types of changes seen for the peptide when it
is titrated with increasing amounts of the order-inducing solvent tri-
ﬂuoroethanol (Suppl. Fig. 3a). In both cases the changes are consistent
with increases in ordered structures given the small size and ﬂexibility
of the peptides. When binding the substrate, however, the spectral
change appears to be more like that associated with beta-strand
formation (as suggested by the sequence-based prediction) rather
than with formation of a helical structure.
Additionally, in order to investigate whether the CoA portion of the
substrate alone could interact with Sit1, the peptide was incubated
with CoA molecules (Fig. 3B). In this case, virtually no alteration in the
CD spectrumwas observed, suggesting that the peptide–substrate bind-
ing is likely to be due primarily to an interaction with the acyl-chain of
the substrate (OCoA). Hence, the solution SRCD studies are consistent
with Sit1 being a potential site of interaction for the acyl-CoA substrate,
as had been suggested by the sequence homology with the acyl-CoA
cholesterol acyltransferase (ACAT) enzymes which have this substrate
in common with DGAT, and by mutational studies in this region for
yeast ACAT1 [26].
In contrast, the spectra of Sit2 and Sit1&2 alone include a large
negative peak at around 195 nm, and no positive peaks at either low
or high wavelengths, which suggests that they are almost entirely
unstructured (Fig. 3C and D). When even small amounts of OCoA are
introduced, the solution became turbid, accompanied by a large
decrease in the SRCD high tension voltage (HT) signal (which reﬂects
the peptide concentration in solution), suggesting that aggregation
had occurred. This prevented the measurement of both the SRCD and
ﬂuorescence spectra with this substrate.
3.4. Fluorescence spectroscopy
The ﬂuorescence emission spectra of the DGAT1 peptides in an
aqueous solution (Fig. 3E, G, H) were in agreement with them being
in a disordered state, with the Trp residues exposed to the solvent,producing a maximum ﬂuorescence emission (λmax) centered at
355 nm [27–29].
When Sit1 peptide was incubated with the OCoA (Fig. 3E), a blue
shift to ~340 nm was observed. Upon titration with this substrate, the
ﬂuorescence intensity of Sit1 gradually decreased, in agreement with
the interaction of this peptide as seen by SRCD spectroscopy. As a
control to eliminate the possibility that substrate-induced ﬂuorescence
quenching of the peptide was responsible for the changes, oleoyl-CoA
was added to the peptide analogue N-acetyl-tryptophan (data not
shown) and shown to have no effect.
Moreover, as with the SRCD studies, the ﬂuorescence emission
spectra of Sit1 did not change in the presence of CoA group alone
(Fig. 3F). In contrast, the ﬂuorescence emission spectra of Sit2 and
Sit1&2 in the presence of the CoA group were blue shifted of ~15 nm
and increased in intensity by ~15%. These effects were in agreement
with an ordering promoted on the peptide's structure due to the inter-
actions between peptides with the charged CoA group (Fig. 3G and H).
3.5. SRCD spectroscopy of ﬁlms
The DOG substrate is not water-soluble, hence preventing solution
binding studies from being done. Therefore, SRCD spectroscopy [30,
31] was used to examine the interactions between the peptides with
both the substrate (DOG) and the non-substrate analogue (POPG)
prepared as ﬁlms.
Fig. 4 shows the oriented SRCD (oSRCD) spectra of the DGAT
peptides in the presence of hydrated ﬁlms of DOG and POPG. In general,
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solution, as is often the case, even if there are no speciﬁc interactions
with the ﬁlm molecules. There is some suggestion from the shapes of
the curves and positions of the peaks associated with the differently
oriented transitions, that they lie along the ﬁlm surface rather than
being incorporated perpendicularly into the ﬁlms (but not as helices).
Again, in this case we have prudently not attributed speciﬁc types of
spectra with speciﬁc types of structure, especially as exemplar spectra
for differently oriented beta sheets have not yet been deﬁned. However,
it is notable that the spectra for Sit1 are quite similar on both types of
ﬁlms suggesting that their interactions are not compound-speciﬁc. On
the other hand, Sit2 clearly produces different spectra on the two
types of lipids, suggesting speciﬁcity of interaction. The Sit1&2 oSRCD
spectra are similar on both cognate and non-cognate substrates, with
one exception: there is an extra peak at ~195 nm in the POPG ﬁlm,
perhaps indicative of differential interactions of this peptide also.
4. Conclusions
The interactions of DGAT1 peptides that had been proposed to
incorporate binding sites for different substrates and non-substrates of
the triacylglycerol catalysis reaction have been examined using spectro-
scopic andmonolayermethods. Such studies are experimental evidence
for the interaction of the luminal extramembranous domain of the
DGAT1 enzymes binding the speciﬁc substrates for triacylglyceride
synthesis. Knowledge of the nature of the interactions involved in the
binding of the substrates to their binding sitesmay be useful in the search
for, and the design of, potent inhibitors for the DGAT1 enzymes [32].
Sit1 appears to speciﬁcally bind the OCoA substrate but not the non-
substrate analogueCoA in an aqueous solution, suggesting that indeed it
does incorporate a binding site for this substrate, while Sit2 displays
differential types of interaction with the other substrate (DOG) versus
the non-substrate (POPG) lipid in the ﬁlms.
This study has indicated that while the Sit2 peptide (predicted DAG
binding site) is located in a large extra-membranous loop rather than in
a transmembrane segment, it is capable of interacting with the
membrane-bound substrate DAG. This somewhat unexpected ﬁnding
of the binding site for the membrane bound substrate being localized
within the aqueous compartment suggests that this interaction may
create an optimal motif and juxtaposition enabling molecular
recognition.
Moreover, the combination peptide Sit1&2 exhibited enhanced
interactions with substrates, as shown in the SRCD ﬁlm changes with
the DOG. The two binding sites may act in concert using a combination
of hydrophobic and electrostatic interactions. We therefore propose
that the predicted putative binding sites might work synergistically
to bring the triacylglycerol substrates into close proximity near
membrane, so that the proposed active site histidine, also located in
the same extramembranous loop, can catalyze the formation of the
triacylglyceride product.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2014.08.017.
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